|Company name||Eidos Therapeutics, Inc.|
NEW YORK, April 1, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against Eidos Therapeutics, Inc. (NASDAQ: EIDX). Our investigation concerns whether Eidos has violated the federal securities laws and/or engaged in other unlawful business practices.
On April 1, 2019, after the market closed, Eidos filed a Form 8-K with the SEC announcing that its previously issued financial statements for the first three quarterly periods in the year ended December 31, 2018 could no longer be relied upon.
If you purchased or otherwise acquired Eidos shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.